openPR Logo
Press release

Global CD233 Antibody Market Clinical Trials Intelligence 2028

12-23-2021 11:04 AM CET | Health & Medicine

Press release from: Kuick Resarch

Global CD233 Antibody Market Clinical Trials Intelligence 2028

Global CD233 Inhibitors Trials Intelligence Report Highlights:

• Global CD233 Inhibitors Market Dynamics
• Clinical Approaches to Target CD233 Inhibitors
• Role of CD233 Inhibitors in Cancer, Autoimmune Disorders
• Number of CD233 Inhibitors Drug In Trials
• CD233 Inhibitors Approved Patent Insight
• CD233 Inhibitors Trials By Phase, Company, Country, Indication
• Company Agreement/Partnership/Deals For Ongoing Trials
• Global CD233 Inhibitor Market Future Outlook

For Report Sample Contact neeraj@kuickresearch.com

The successful application of the anti-CTLA-4 and anti-PD-1/PD-L1 mAbs has paved the way to a new era of anticancer therapy changing the therapeutic scenario in a number of tumor settings. However, clinical benefit is still limited to a subset of patients, which is likely due to the heterogeneity of the cancer immunogenic profile during growth and dissemination, and acquisition of resistance mechanisms. Further, co-administration of PD-1/PD-L1 and CTLA-4 inhibitor has strengthened the evidence that the combination of drugs targeting different immune checkpoint regulatory pathways is a feasible approach to improve treatment efficacy and potentially delay or prevent tumor resistance.

The better understanding about tumor microenvironment and has led to identification of several co-stimulatory receptors including CD223, TIM-3, and TIGIT, which display functional redundancy with CTLA-4 and PD-1/PD-L1 axes. Among all, CD223 or lymphocyte activation gene-3 has gained considerable interest among research institutions and pharmaceutical sectors. CD223 is an immune checkpoint receptor protein found on the cell surface of effector T cells and regulatory T cells (Tregs) and functions to control T cell response, activation, and growth. In addition to this, these molecules are also expressed in tumor microenvironment which makes them potential target in cancer immunotherapy.

The identification of novel immunoreceptor has surged the development of novel CD223 targeting drugs in preclinical and clinical development. Several potential inhibitors including Relatlimab, IMP321, LAG525, MGD013, MK4280, FS118, and other are present in early phase of clinical development and will transform the cancer immunotherapy in 4-5 years. Recently in 2021, Relatlimab has received priority review from US FDA and it is expected to enter the market by 2022. The entrance of these drugs in the market by next year is expected to transform the overall cancer therapeutics market. It is expected that the market will be inclined more towards immunotherapy in coming years which is mainly due to their ability to overcome PD-1/PD-L1 drug resistance in cancer patients.

Beyond the inhibitory activity of CD223 on different types of cancers, CD223 may also be necessary to negatively regulate autoimmunity in many disease-prone environments. For instance, loss of LAG-3 substantially can accelerate type 1 diabetes in Non-Obese Diabetic (NOD) mice with 100% incidence. LAG-3 deficient mice can exhibit increased antigen-reactive CD4+ and CD8+ T cells infiltration in the islets, accompanied by invasive and rapid insulitis. Therefore, researchers are also expanding their knowledge of targeting CD223 signaling pathways as an alternative approach to manage other therapeutic indications, which is further boosting the market growth.

The global CD223 targeted therapeutics is expected to surpass US$ XX Billion by 2028. The growing burden of critical diseases such as cancer, leukemia, lymphoma, and muscular degeneration are the major factors that boost the adoption of CD223 targeting drugs among the global population. The growing adoption of technological advancements in the field of biopharmaceutical and rising consumer awareness regarding the safety of the CD223 targeted therapeutics will also be fueling the market growth during the forecast period. In addition, the increased efficiency of the novel CD223 targeted drugs to treat such deadly diseases with minimal side effects is also major driving factor of the market.

US is expected to be the leading consumer of the CD223 targeted therapeutics owing to the increased adoption rate and higher demand for the advanced and innovative products. The rapidly booming biologics industry is a significant factor that propels the growth of the targeted therapeutics market in US. Further, the presence of numerous CMOs and CROs along with the various biopharmaceutical companies together contributes towards the market development. Moreover, the rising geriatric population, increased disposable income, presence of high-end technologies and developed healthcare infrastructure, and rising demand for the biologic drugs is fueling the growth of the targeted therapeutics in US.

Contact:

Neeraj Chawla
Research Head
Kuick Research
neeraj@kuickresearch.com
+919810410366

Delhi
India

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global CD233 Antibody Market Clinical Trials Intelligence 2028 here

News-ID: 2509218 • Views: 144

More Releases from Kuick Resarch

Lumakras Drug Clinical Insight and Sales Forecast 2026
"Lumakras Drug Clinical Insight and Sales Forecast 2026" Report Highlights: * NSCLC Targeting Lumakras Market Opportunity (US$ Million) * Colorectal Cancer Targeting Lumakras Market Opportunity (US$ Million) * Pharmacokinetics of Lumakras (Sotorasib) * Dosage, Patent and Price Analysis * Lumakras Ongoing Clinical Trials * Global KRAS Protein Inhibitors Clinical Trials Download Report: https://www.kuickresearch.com/report-lumakras-sotorasib-sales-forecast-fda-approved-kras-inhibitor-clinical-trials-non-small-cell-lung-cancer-nslc-g12c-mutation-c30h30f2n6o3-ras-gtpase The rising burden of cancer and the increasing cancer mortality rates possesses an unmet need for the development of novel therapies in the management
Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026
"Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026" Report Highlights: * Global EZH2 Inhibitor Market Opportunity > US$ 1.2 Billion by 2026 * Tazverik (Tazemetostat) First Approved EZH2 Inhibitor Drug * Dosage, Price and Sales Analysis of Tazverik * Tazverik Sales Opportunity > US$ 900 Million by 2026 * Tazverik Sales Forecast 2021 Till 2026 * EZH2 Inhibitor Clinical Pipeline Overview By Company, Indication and Phase * EZH2 Inhibitor in Clinical Trials: 7 Drugs Download
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Tr …
"Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028" Report Highlights: * Global Bispecific Antibody Market Opportunity: > US$ 20 Billion * Global Bispecific Antibody Market Growth Rate: 100% CAGR (2016 -2021) * Approved Bispecific Antibodies In Market: 4 Antibodies * Detailed Market Sales and Trends Insight Till 2028 * Quarterly and Yearly Sales Insight Of Approved Antibodies Till Q1 2022 * Global and Regional Market Analysis * Approved Drug Sales
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and C …
"Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026" Report Highlights: * Global FGFR Inhibitors Market Opportunity: > USD 4 Billion by 2026 * Role of FGFR Inhibitors in Cancer Therapy * Global FGFR Market Assessment (US$) by Region and Cancer Type Clinical and Sales Insight on Approved FGFR Inhibitors: 3 (Belvesra, Pemazyre and Truseltiq) * Dosage and Drug Price Insight on Approved FGFR Inhibitors * Comprehensive Clinical Trials Insight

All 5 Releases


More Releases for CD223

Cancer Immunotherapies Market Trends, Share, Size, Statistics, Outlook, Analysis …
Cancer Immunotherapies has brought an unprecedented change in the global cancer therapies market. Cancer immunotherapy can be defined as, the treatment that deploys the bodys immune system, by joining and boosting innate powers of the immune system to fight cancer. Download Free Sample Report@ https://www.alliedmarketresearch.com/request-sample/1466 Cancer Immunotherapies Market Competitive Analysis: Leading market players Johnson & Johnson, AstraZeneca plc, GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Pfizer, Inc., F. Hoffman-La Roche AG, Advaxis,
CD Antigen Cancer Therapy Market Outlook & Clinical Trials Insight 2023
“CD Antigen Cancer Therapy Market Outlook & Clinical Trials Insight 2023” report gives comprehensive insight into multiple clinical and non-clinical issues related to emergence and development of global CD Antigen cancer therapy market. CD Antigens have emerged as new growth frontier for the organizations involved in the research, development, licensing and commercialization of targeted cancer therapies. CD antigens have been present in disguise since the efforts began to develop
In Depth Research on
“Cancer CD Antigens Inhibitors Therapy Market & Pipeline Insight 2015” Report Highlight: * Nomenclature & Classification of CD Antigens * Mechanism of CD Antigen Cancer Therapeutics * Cancer CD Antigen Therapy Market Overview * Cancer CD Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase * Cancer CD Antigen Inhibitors Clinical Pipeline: 207 Drugs * Marketed Cancer CD Antigen Inhibitors: 27 Drugs * Majority of Cancer CD Antigen Inhibitors in Preclinical Phase: 70 Drugs * Cancer CD Antigens
Competitor Analysis: Inhibitory and Stimulatory Immunomodulators in Immuno-Oncol …
MarketResearchReports.Biz presents this most up-to-date research on "Competitor Analysis: Inhibitory and Stimulatory Immunomodulators in Immuno-Oncology" Description Competitor Analysis: Inhibitory and Stimulatory Immunomodulators in Immuno-Oncology This product consists of four reports in pdf format describing the competitive field of new molecular entities directed against inibitory as well stimulatory immune checkpoints on T-cells, antigen presenting cells (APCs)/dendritic cells or tumor cells and against immunosuppressive factors in the tumor microencironment, including Treg cells, tumor-associated macrophages (TAM),
Competitor Analysis: Inhibitory and Stimulatory Immunomodulators in Immuno-Oncol …
MarketResearchReports.Biz presents this most up-to-date research on "Competitor Analysis: Inhibitory and Stimulatory Immunomodulators in Immuno-Oncology" Description Competitor Analysis: Inhibitory and Stimulatory Immunomodulators in Immuno-Oncology This product consists of four reports in pdf format describing the competitive field of new molecular entities directed against inibitory as well stimulatory immune checkpoints on T-cells, antigen presenting cells (APCs)/dendritic cells or tumor cells and against immunosuppressive factors in the tumor microencironment, including Treg cells, tumor-associated macrophages (TAM),
Inhibitory and Stimulatory Immunomodulators in Immuno-Oncology Market Report 201 …
Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “Competitor Analysis: Inhibitory and Stimulatory Immunomodulators in Immuno-Oncology” to its report offerings. This product consists of four reports in pdf format describing the competitive field of new molecular entities directed against inibitory as well stimulatory immune checkpoints on T-cells, antigen presenting cells (APCs)/dendritic cells or tumor cells and against immunosuppressive factors in the tumor microencironment, including